spacer
home > epc > spring 2002 > uk phase i/iia cros - the challenges ahead
PUBLICATIONS
European Pharmaceutical Contractor

UK Phase I/IIa CROs - The Challenges Ahead

The EU Clinical Trials Directive

The implementation of the EU Clinical Trials Directive across member states will undoubtedly bring about a 'levelling of the playing field' as Phase I/IIa contract research organisations (CROs) compete for early phase clinical trials from pharmaceutical and biotechnology companies. With the additional burden of the strength of the pound at present, Phase I/IIa CROs in the UK face increasing commercial competition from their European counterparts and those based in the US and Canada.

UK Phase I/IIa CROs are currently able to offer pharma and biotechnology companies - particularly those in North America - faster clinical trial 'start-up' times in the early development of their compounds, as these trials do not require notification or approval by the national regulatory agency.

The cost and time benefits (particularly for smaller start-up companies) has meant that the UK has had a distinct commercial edge in attracting such trials. Implementation of the EU Clinical Trials Directive will not only provide greater harmonisation across European member states in terms of ethical and regulatory processes and clinical trial supply manufacture, but will create a more level playing field between UK CROs and their European and North American competitors. As early phase trials in the UK will now require regulatory approval, a key commercial advantage has been removed.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Wayne Griffin, Managing Director of Acumen Pharmaceutical Services Ltd

Wayne Griffin is Managing Director of Acumen Pharmaceutical Services Ltd, an early phase product development CRO based in Manchester, UK. He has more than 20 years' experience of working in the pharmaceutical industry, gaining scientific and managerial experience spanning all aspects of clinical development within several companies.
After graduating from the University of Surrey in 1980 he undertook a PhD at the University of London's cardiothoracic unit at Brompton Hospital in London, where he conducted various clinical research projects in cardiology and respiratory medicine. Wayne was previously Director of Clinical Research at an international CRO, and co-founded Acumen Pharmaceutical Services Ltd in 1998.

spacer
Wayne Griffin
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

CPhI China opens with analysis pointing to a surge in growth in 2019

Shanghai, 23rd May 2019: New analysis released ahead of CPhI & P-MEC China (#CPhIChina and #PMECChina) – co-organized by Informa Markets, CCCMHPIE, and Shanghai Sinoexpo Informa Markets – forecasts that China will continue to grow strongly through 2019/20, thanks in part to a marked improvement in its global reputation.
More info >>

White Papers

Customising the Cold Chain

World Courier

Of all the statistics emerging around the global pharmaceutical industry this year, two big numbers capture the attention of both manufacturers and their logistics partners: $248 billion, the amount the “BRIC” nations (Brazil, Russia, India and China) are poised to account for in pharmaceutical sales for by 2016; and $8 billion, the amount global pharma will spend on cold chain logistics in 2014. Why are these two numbers so noteworthy? They demonstrate that as R&D goes, so goes logistics. As products evolve to meet demands for more targeted therapies, demand for more targeted logistics solutions grows as well. And that means a need for customization for everything from clinical trial samples to finished product.
More info >>

 
Industry Events

World Pharma Week 2019

17-20 June 2019, Seaport World Trade Center, Boston

World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement